Daniel Lorca-Arce

Daniel Lorca-Arce

Auto-generated profile, based on publicly available information

Daniel Lorca-Arce

Immunology Service Hospital Clinic Barcelona Barcelona Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
JCJose Maria Cabrera-Maqueda
Jose Maria Cabrera-Maqueda
MSMaria Sepulveda
Maria Sepulveda
RGRaquel Ruiz García
Raquel Ruiz García
GMGuillermo Muñoz-Sánchez
Guillermo Muñoz-Sánchez
NMNuria Martínez-Cibrian
Nuria Martínez-Cibrian
YBYolanda Blanco
Yolanda Blanco
In MOG antibody-associated disease (MOGAD), relapse prevention and the treatment approach to refractory symptoms are unknown. We report a patient with refractory MOGAD treated with CD19-directed CAR T-cells. CD19-directed CAR T-cells (ARI-0001) were produced in-house by lentiviral transduction of autologous fresh leukapheresis and infused after a conventional lymphodepleting regimen. A 18-year-old man developed 2 episodes of myelitis associated with serum MOG-IgG, which were followed by 6 episodes of left optic neuritis (ON) and sustained the presence of MOG-IgG over 6 years despite multiple immunotherapies. After the sixth episode of ON, accompanied by severe residual visual deficits, CAR T-cell treatment was provided without complications. Follow-up of cell counts showed complete depletion of CD19+ B cells at day +7; reconstituted B cells at day +141 showing a naïve B-cell phenotype, and low or absent memory B cells and plasmablasts for 1 year. MOG-IgG titers have remained undetectable since CAR T-cell infusion. The patient had an early episode of left ON at day +29, when MOG-IgG was already negative, and since then he has remained free of relapses without immunotherapy for 1 year. This clinical case shows that CD19-directed CAR T-cell therapy is well-tolerated and is a potential treatment for patients with refractory MOGAD. This provides Class IV evidence. It is a single observational study without controls.

13 October 2022 in HLA
Verified
Journal Article
Closed access
JBJennifer Bolaños
Jennifer Bolaños
DLDaniel Lorca‐Arce
Daniel Lorca‐Arce
CPCristina Arnaldos Pérez
Cristina Arnaldos Pérez
DMDaniel Marti‐Morente
Daniel Marti‐Morente
CSCarles Serra‐Pages
Carles Serra‐Pages

13 March 2023 in HLA
Verified
Journal Article
Open access
DLDaniel Lorca‐Arce
Daniel Lorca‐Arce
DMDaniel Marti‐Morente
Daniel Marti‐Morente
CPCristina Arnaldos Pérez
Cristina Arnaldos Pérez
JBJennifer Bolaños
Jennifer Bolaños
CSCarles Serra‐Pages
Carles Serra‐Pages
A novel HLA‐DRB1*04 allele, officially designated HLA‐DRB1*04:361, was identified by next‐generation sequencing.

9 May 2024 in Heliyon
Verified
Journal Article
Open access
DLDaniel Lorca-Arce
Daniel Lorca-Arce
APAlbert Pérez-Isidro
Albert Pérez-Isidro
JBJudit Becerra
Judit Becerra
MMMaria José Martínez
Maria José Martínez
NMNoemí De Moner
Noemí De Moner
EREstibaliz Ruiz-Ortiz
Estibaliz Ruiz-Ortiz
Anti-dsDNA, anti-Sm, and anti-ribosomal-P autoantibodies are hallmarks of systemic lupus erythematosus (SLE), being anti-dsDNA and anti-Sm included in 2019-ACR/EULAR SLE-Classification Criteria. Enzyme-linked (ELISA) and chemiluminescence assays (CIA) are widely established in immunology laboratories, but new technologies, such as particle-based multi-analyte technology (PMAT), are nowadays available. The present study aimed to compare the presence of anti-dsDNA and anti-Sm autoantibodies measured by CIA and PMAT and analyze diagnostic and clinical SLE activity performance. Anti-ribosomal-P autoantibodies by PMAT were also included. Consequently, anti-dsDNA and anti-Sm detected by CIA showed substantial agreement with PMAT (Cohen's kappa = 0.662 and 0.671, respectively). Anti-dsDNA autoantibodies measured by PMAT showed a positive correlation with clinical SLEDAI-2K (p < 0.001) and a negative correlation with complement consumption (p < 0.001). Anti-Sm and anti-ribosomal-P autoantibodies showed a positive correlation with SLEDAI-2K (p < 0.001 and p = 0.001, respectively) and a negative correlation with complement consumption (p < 0.001 and p = 0.001, respectively). Finally, anti-Sm autoantibodies were associated with renal involvement (p < 0.05).